|Bid||37.13 x 1200|
|Ask||37.28 x 800|
|Day's Range||36.32 - 38.06|
|52 Week Range||29.28 - 58.35|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.00|
Omeros (OMER) announces initial results from a phase I study of OMS906.
It hasn't been the best quarter for Xencor, Inc. ( NASDAQ:XNCR ) shareholders, since the share price has fallen 14% in...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT.